Y
Yael C Cohen
Researcher at Tel Aviv University
Publications - 19
Citations - 476
Yael C Cohen is an academic researcher from Tel Aviv University. The author has contributed to research in topics: Multiple myeloma & Daratumumab. The author has an hindex of 7, co-authored 19 publications receiving 207 citations. Previous affiliations of Yael C Cohen include Tel Aviv Sourasky Medical Center.
Papers
More filters
Journal ArticleDOI
Single cell dissection of plasma cell heterogeneity in symptomatic and asymptomatic myeloma
Guy Ledergor,Guy Ledergor,Assaf Weiner,Mor Zada,Shuang-Yin Wang,Yael C Cohen,Yael C Cohen,Moshe E. Gatt,Moshe E. Gatt,Nimrod Snir,Nimrod Snir,Hila Magen,Hila Magen,Maya Koren-Michowitz,Katrin Herzog-Tzarfati,Hadas Keren-Shaul,Chamutal Bornstein,Ron Rotkopf,Ido Yofe,Eyal David,Venkata Yellapantula,Sigalit Kay,Moshe Salai,Moshe Salai,Dina Ben Yehuda,Dina Ben Yehuda,Arnon Nagler,Arnon Nagler,Lev Shvidel,Lev Shvidel,Avi Orr-Urtreger,Avi Orr-Urtreger,Keren Bahar Halpern,Shalev Itzkovitz,Ola Landgren,Jesús F. San-Miguel,Bruno Paiva,Jonathan J Keats,Elli Papaemmanuil,Irit Avivi,Irit Avivi,Gabriel I. Barbash,Amos Tanay,Ido Amit +43 more
TL;DR: This work establishes single cell RNA sequencing for dissecting blood malignancies and devising detailed molecular characterization of tumor cells in symptomatic and asymptomatic patients, and identifies extensive subclonal structures for 10 of 29 individuals with multiple myeloma.
Journal ArticleDOI
Identification of resistance pathways and therapeutic targets in relapsed multiple myeloma patients through single-cell sequencing.
Yael C Cohen,Yael C Cohen,Mor Zada,Mor Zada,Shuang-Yin Wang,Chamutal Bornstein,Eyal David,Adi Moshe,Baoguo Li,Shir Shlomi-Loubaton,Moshe E. Gatt,Chamutal Gur,Chamutal Gur,Noa Lavi,Chezi Ganzel,Efrat Luttwak,Efrat Luttwak,Evgeni Chubar,Ory Rouvio,Iuliana Vaxman,Iuliana Vaxman,Oren Pasvolsky,Oren Pasvolsky,Mouna Ballan,Tamar Tadmor,Anatoly Nemets,Osnat Jarchowcky-Dolberg,Olga Shvetz,Meirav Laiba,Ofer Shpilberg,Najib Dally,Irit Avivi,Irit Avivi,Assaf Weiner,Ido Amit +34 more
TL;DR: In this article, a prospective, multicenter, single-arm clinical trial (NCT04065789), combined with longitudinal single-cell RNA-sequencing (scRNA-seq) was conducted to study the molecular dynamics of MM resistance mechanisms.
Journal ArticleDOI
Humoral response rate and predictors of response to BNT162b2 mRNA COVID19 vaccine in patients with multiple myeloma.
Irit Avivi,Irit Avivi,Roi Balaban,Tamir Shragai,Tamir Shragai,Gabi Sheffer,Miguel Morales,Anat Aharon,Noa Lowenton-Spier,Svetlana Trestman,Chava Perry,Chava Perry,Noam Benyamini,Noam Benyamini,Moshe Mittelman,Moshe Mittelman,Yaara Tabib,Yaara Tabib,Tali Bar Lev,Tali Bar Lev,Mor Zavaro,Mor Zavaro,Yair Herishanu,Yair Herishanu,Efrat Luttwak,Efrat Luttwak,Yael C Cohen,Yael C Cohen +27 more
TL;DR: In conclusion, BNT162b2 vaccine was safe and provided a high seropositivity rate in MM patients, independent of treatment type, and older, hypogammaglobulinaemic and heavily pretreated patients had lower response rates.
Journal ArticleDOI
Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS).
C. Ola Landgren,Ajai Chari,Yael C Cohen,Andrew Spencer,Peter M. Voorhees,Jane Estell,Irwindeep Sandhu,Matthew W Jenner,Catherine D. Williams,Michele Cavo,Niels W.C.J. van de Donk,Meral Beksac,Philippe Moreau,Hartmut Goldschmidt,Steven Kuppens,Rajesh Bandekar,Pamela L. Clemens,Tobias Neff,Christoph Heuck,Ming Qi,Craig C. Hofmeister +20 more
TL;DR: In the CENTAURUS trial as mentioned in this paper, patients with intermediate-risk or high-risk multiple myeloma (SMM) were randomly assigned to daratumumab 16 mg/kg intravenously on extended intense (intense), extended intermediate (intermediate), or short dosing schedules.
Journal ArticleDOI
Correlation between BNT162b2 mRNA Covid-19 vaccine-associated hypermetabolic lymphadenopathy and humoral immunity in patients with hematologic malignancy.
Dan Cohen,Shir Hazut Krauthammer,Yael C Cohen,Yael C Cohen,Chava Perry,Chava Perry,Irit Avivi,Irit Avivi,Yair Herishanu,Yair Herishanu,Einat Even-Sapir,Einat Even-Sapir +11 more
TL;DR: VAHL on [18F]FDG PET-CT of patients with hematologic malignancy may reflect GC B-cell proliferation and an effective humoral response elicited by BNT162b2 vaccine.